U.S. markets close in 1 hour 17 minutes
  • S&P 500

    4,208.84
    -37.75 (-0.89%)
     
  • Dow 30

    33,967.16
    -332.17 (-0.97%)
     
  • Nasdaq

    13,933.41
    -139.45 (-0.99%)
     
  • Russell 2000

    2,305.54
    -14.54 (-0.63%)
     
  • Crude Oil

    71.99
    -0.13 (-0.18%)
     
  • Gold

    1,843.10
    -13.30 (-0.72%)
     
  • Silver

    27.55
    -0.15 (-0.53%)
     
  • EUR/USD

    1.2025
    -0.0108 (-0.89%)
     
  • 10-Yr Bond

    1.5430
    +0.0440 (+2.94%)
     
  • GBP/USD

    1.4013
    -0.0069 (-0.49%)
     
  • USD/JPY

    110.4930
    +0.4590 (+0.42%)
     
  • BTC-USD

    38,488.46
    -2,579.39 (-6.28%)
     
  • CMC Crypto 200

    955.09
    -37.38 (-3.77%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 2777865. To access a live webcast and subsequent archived recording of the call, please visit "Events" in the "Investors" section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005101/en/

Contacts

Investor Contact:
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200